EP Patent

EP1853250B1 — Combinations and modes of administration of therapeutic agents and combination therapy

Assigned to Abraxis Bioscience LLC · Expires 2011-11-02 · 15y expired

What this patent protects

Provided herein is a composition comprising nanoparticles comprising paclitaxel and an albumin for use in a method for the treatment of cancer in an individual, wherein the method further comprises administering an antimetabolite.

USPTO Abstract

Provided herein is a composition comprising nanoparticles comprising paclitaxel and an albumin for use in a method for the treatment of cancer in an individual, wherein the method further comprises administering an antimetabolite.

Drugs covered by this patent

Patent Metadata

Patent number
EP1853250B1
Jurisdiction
EP
Classification
Expires
2011-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.